GT Biopharma Inc. held its annual meeting of stockholders on July 24, 2025. During the meeting, four members were elected to the Board of Directors, including Michael Breen, Charles J. Casamento, Hilary Kramer, and David C. Mun-Gavin. The appointment of Weinberg & Company, P.A. as independent accountants for the year ending December 31, 2025, was ratified. The amendment to the GT Biopharma, Inc. 2022 Omnibus Incentive Plan, increasing the number of shares available for future awards by 583,334 shares of Common Stock, was approved. The issuance of 19.99% or more of the outstanding shares of Common Stock, as outlined in the Securities Purchase Agreement and the Common Shares Purchase Agreement, was also approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.